PROCEPT BioRobotics (PRCT) Cost of Revenue (2020 - 2026)

PROCEPT BioRobotics (PRCT) has 7 years of Cost of Revenue data on file, last reported at $29.2 million in Q1 2026.

• Quarterly Cost of Revenue rose 16.74% year-over-year to $29.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $116.0 million (up 24.89% YoY) and the FY2025 annual result came in at $111.8 million, up 27.95% from the prior year.
• Cost of Revenue eased to $29.2 million in Q1 2026 per PRCT's latest filing, from $30.1 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $30.1 million in Q4 2025 and bottomed at $6.5 million in Q1 2022.
• The 5-year median for Cost of Revenue is $21.5 million (2024), against an average of $19.5 million.
• The widest annual swing landed in 2022, when Cost of Revenue soared 133.03%; it then increased 10.02% in 2024.
• Tracing PRCT's Cost of Revenue over 5 years: stood at $13.1 million in 2022, then surged by 70.41% to $22.3 million in 2023, then grew by 10.02% to $24.6 million in 2024, then rose by 22.41% to $30.1 million in 2025, then declined by 2.94% to $29.2 million in 2026.
• Per Business Quant, the three latest PRCT Cost of Revenue figures stand at $29.2 million (Q1 2026), $30.1 million (Q4 2025), and $29.3 million (Q3 2025).

Peer Comparison